Dr. Reddy’s RDY slides after Q4 profit plunges 86% on weaker sales
RDY•Dr. Reddy’s reported Q4 FY26 results today showing an 86% drop in consolidated profit after tax to ₹221.3 crore and an 11.51% revenue decline, driven by weaker North America generics sales. The stock’s drop aligns with investors reacting to the same-day earnings release.
1) What happened today
Dr. Reddy’s Laboratories released quarterly results on May 12, 2026, reporting a sharp earnings deterioration. Consolidated profit after tax fell 86% to ₹221.3 crore and revenue declined 11.51% for the quarter ended March 31, 2026, with the weakness attributed to lower generics sales in North America. (business-standard.com)
2) Why it matters for the stock move
A same-day earnings release is a concrete catalyst that can reset expectations for near-term growth and profitability, especially when results show a pronounced year-over-year profit decline. The timing matches today’s U.S. session move in RDY, making the results the most direct, dated driver identified in today-published coverage. (business-standard.com)
3) What to watch next
Investors will likely focus on management’s explanation of the North America generics slowdown, any margin or cost actions, and whether the company provided updated expectations for upcoming quarters. Any additional details from the earnings communication/call could further influence RDY’s next move.
